Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 52, 2018 - Issue 2
Journal homepage
171
Views
13
CrossRef citations to date
0
Altmetric
Article

High inducible nitric oxide synthase in prostate tumor epithelium is associated with lethal prostate cancer

Ann ErlandssonDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; ;Department of Environmental and Life Sciences/Biology, Karlstad University, Karlstad, Sweden; Correspondence[email protected]
View further author information
,
Jessica CarlssonDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
,
Sven-Olof AnderssonDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
,
Chraig VyasDepartment of Epidemiology, Boston University School of Public Health, Boston, MA, USA; View further author information
,
Pernilla WikströmDepartment of Medical Biosciences, Umeå University, Umeå, SwedenView further author information
,
Ove AndrénDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
,
Sabina DavidssonDepartment of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; View further author information
&
Jennifer R. RiderDepartment of Epidemiology, Boston University School of Public Health, Boston, MA, USA; View further author information
 show all
Pages 129-133 | Received 04 Aug 2017, Accepted 17 Dec 2017, Published online: 08 Jan 2018

References

  • Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27.
  • Ekmekcioglu S, Ellerhorst JA, Prieto VG, et al. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006;119:861–866.
  • Saied EM, El-Etreby NM. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours. Ann Diagn Pathol. 2017;27:62–68.
  • Yang L, Wang Y, Guo L, et al. The expression and correlation of iNOS and p53 in oral squamous cell carcinoma. Biomed Res Int. 2015;2015:637853.
  • Burke AJ, Garrido P, Johnson C, et al. Inflammation and nitrosative stress effects in ovarian and prostate pathology and carcinogenesis. Antioxid Redox Signal. 2017;26:1078–1090.
  • Choudhari SK, Chaudhary M, Bagde S, et al. Nitric oxide and cancer: a review. World J Surg Oncol. 2013;11:118.
  • Bogdan C. Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol. 2015;36:161–178.
  • Lee KM, Kang D, Park SK, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis. 2009;30:621–625.
  • Qidwai T, Jamal F. Inducible nitric oxide synthase (iNOS) gene polymorphism and disease prevalence. Scand J Immunol. 2010;72:375–387.
  • Wang J, Torbenson M, Wang Q, et al. Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol. 2003;21:117–122.
  • Aaltomaa SH, Lipponen PK, Viitanen J, et al. The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int. 2000;86:234–239.
  • Aaltoma SH, Lipponen PK, Kosma VM. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res. 2001;21:3101–3106.
  • Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13:1472–1479.
  • Davidsson S, Ohlson AL, Andersson SO, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2013;26:448–455.
  • Davidsson S, Fiorentino M, Andrén O, et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2280–2287.
  • Salim A, Ma X, Fall K, et al. Analysis of incidence and prognosis from 'extreme' case-control designs. Stat Med. 2014;33:5388–5398.
  • Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100:815–825.
  • Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012;7:e47045.
  • Klotz T, Bloch W, Volberg C, et al. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer. 1998;82:1897–1903.
  • Baltaci S, Orhan D, Gögüs C, et al. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int. 2001;88:100–103.
  • Ozgur T, Atik E, Hakverdi S, et al. The expressions of AMACR and iNOS in prostate adenocarcinomas. Pak J Med Sci. 2013;29:610–613.
  • Gradini R, Realacci M, Ginepri A, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol. 1999;189:224–229.
  • Lundholm M, Hägglöf C, Wikberg ML, et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci Rep. 2015;5:15651.
  • Tapia-Laliena MA, Korzeniewski N, Hohenfellner M, et al. High-risk prostate cancer: a disease of genomic instability. Urol Oncol. 2014;32:1101–1107.
  • Liu W. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl. 2016;18:533–542.
  • Mani RS, Amin MA, Li X, et al. Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer. Cell Rep. 2016;17:2620–2631.
  • Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201:1257–1268.
  • Cronauer MV, Ince Y, Engers R, et al. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene. 2007;26:1875–1884.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.